Skip to main content
SpringerLink
Log in

Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

The aim of the study was to evaluate whether ossein-hydroxyapatite (OHC) is more effective than calcium carbonate (CC) in preventing futher bone loss in postmenopausal osteoporosis. Forty osteoporotic patients were monitored for 20 months. The patients were randomly assigned to one of two groups and treated in a double-masked manner with 1400 mg calcium per day, in the form of either OHC or CC. OHC consists of hydroxyapatite, collagens and non-collagenous proteins/peptides containing insulin-like growth factor I (IGF-I; 1341 ng), insulin-like growth factor II (IGF-II; 670 ng), transforming growth factor beta (TFG-β; 166 ng) and osteocalcin (47 µg). The bone densities were evaluated at intervals of 4 months with high-precision peripheral quantitative computed tomography. After 20 months of treatment the loss of trabecular bone was 0.8±0.5% in the OHC group and 1.8±0.7% in the CC group. The difference between the OHC and CC groups was statistically significant. This study shows that OHC is more effective than CC in slowing peripheral trabecular bone loss in patients with manifest osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sandier RB, Slemenda CW, LaPorte RE, Cauley JA, Schramm MM, Barresi ML, Kriska AM. Postmenopausal bone density and milk consumption in childhood and adolescence. Am J Clin Nutr 1985;42:270–4.

    Google Scholar 

  2. Heaney RP. Calcium intake and bone health. In: Coissac P, editor. Postmenopausal osteoporosis: prevention and treatment. XIth World Congress of Gynecology and Obstetrics, Berlin. Basel: Sandoz, 1985.

    Google Scholar 

  3. Prior JC, Vigna YM, Schechter MT, Burgess AE. Spinal bone loss and ovulatory disturbances. N Engl J Med 1990;323:1221–7.

    Google Scholar 

  4. van Beresteijn ECH, van't Hof MA, Schaafsma G, de Waard H, Duursma SA. Habitual dietary calcium intake and cortical bone loss in perimenopausal women: a longitudinal study. Calcif Tissue Int 1990;47:338–44.

    Google Scholar 

  5. Dawson-Hughes B, Dallal GE, Krall EA, Sadowski L, Sahyoun N, Tannenbaum S. A controlled trial of the effect of calcium supplementation of bone density in postmenopausal women. N Engl J Med 1990;323:878–83.

    Google Scholar 

  6. Cumming RG. Calcium intake and bone mass: a quantitative review of the evidence. Calcif Tissue Int 1990;47:194–201.

    Google Scholar 

  7. Heaney RP. Calcium bone health, and osteoporosis. Bone Miner Res 1986;4:255–301.

    Google Scholar 

  8. Smith KT, Heaney RP, Flora L, Hinders SM. Calcium absorption from a new calcium delivery system (CCM). Calcif Tissue Int 1987;41:351–2

    Google Scholar 

  9. Miller JZ, Smith DL, Flora L, Slemenda C, Jiang XY, Johnston CC Jr. Calcium absorption from calcium carbonate and a new form of calcium (CCM) in healthy male and female adolescents. Am J Clin Nutr 1988;48:1291–4.

    Google Scholar 

  10. Sheikh MS, Santa Ana CA, Nicar MJ, Schiller LR, Fordtran JS. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987;317:532–6.

    Google Scholar 

  11. Dambacher MA, Rüegsegger P. Therapy of osteoporosis with an ossein-hydroxyapatite compound evaluated with quantitative computed tomography. In: Ninth annual scientific meeting of the American Society for Bone and Mineral Research, Indianapolis, 1987.

  12. Stepan JJ, Mohan S, Jennings JC, Wergedal JE, Taylor AK, Baylink DJ. Quantitation of growth factors in ossein mineral compound. Life Sci 1991;49:79–84.

    Google Scholar 

  13. Rüegsegger P. Quantitative bone measurements in the peripheral skeleton. EULAR Bull 1990;4:112–8.

    Google Scholar 

  14. Rüegsegger P, Durand EP, Dambacher MA. Differential effects of aging and disease in trabecular and compact bone density of the radius. Bone 1991;12:99–105.

    Google Scholar 

  15. Rüegsegger P. Quantitative computed tomography at peripheral measuring sites. Ann Chir Gynaecol 1988;77:204–7.

    Google Scholar 

  16. Galasko CSB. Microcrystalline hydroxyapatite in patients with Colles' fractures. In: International symposium on osteoporosis, Copenhagen, 1984.

  17. Nilsen KH, Jayson MIV, Dixon AStJ. Microcrystalline calcium hydroxyapatite compound in corticoid treated rheumatoid patients: a controlled study. BMJ 1973;2:1124.

    Google Scholar 

  18. Pines A, Raafat H, Lynn AH, Whittington J. Clinical trial of microcrystalline hydroxyapatite compound (Ossopan) in the prevention of osteoporosis due to corticosteroid therapy. Curr Med Res Opin 1984;8:734–42.

    Google Scholar 

  19. Sherlock S. Microcrystalline hydroxyapatite compound reverses cortical bone thinning in postmenopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982;36:426.

    Google Scholar 

  20. Stellon A, Davies A, Webb A, Williams R. Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis. Postgrad Med J 1985;61:791–6.

    Google Scholar 

  21. Stepan JJ, Pospichal J, Presl J, Pacovsky V. Prospective trial of ossein-hydroxyapatite compound in surgically induced postmenopausal women. Bone 1989;10:179–85.

    Google Scholar 

  22. Annefeld M, Caviezel R, Schacht E, Schicketanz KH. The influence of ossein-hydroxyapatite compound on the healing of a bone defect. Curr Med Res Opin 1986;10:241–50.

    Google Scholar 

  23. Buclin T, Jacquet AF, Burckhardt P. Absorption intestinale de gluconate de calcium et de complexe osséin-mineral: évaluation par des dosages conventionnels. Schweiz Med Wochenschr 1986;116:1780–3.

    Google Scholar 

  24. Rüegsegger P, Dambacher MA, Rüegsegger E, Fischer JA, Anliker M. Bone loss in premenopausal and postmenopausal women: a cross-sectional and longitudinal study using QCT. Bone Joint Surg [Am] 1984;66:1015–23.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Biomedical Engineering, University and Federal Institute of Technology, Zurich

    P. Rüegsegger

  2. Osteoporosis Center, Liestal

    A. Keller

  3. Research Laboratory for Calcium Metabolism, Orthopaedic University Hospital, Zurich, Switzerland

    M. A. Dambacher

Authors
  1. P. Rüegsegger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. A. Dambacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rüegsegger, P., Keller, A. & Dambacher, M.A. Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females. Osteoporosis Int 5, 30–34 (1995). https://doi.org/10.1007/BF01623655

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01623655

Keywords

Search

Navigation